DK3271392T3 - Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia - Google Patents

Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia Download PDF

Info

Publication number
DK3271392T3
DK3271392T3 DK16720043.5T DK16720043T DK3271392T3 DK 3271392 T3 DK3271392 T3 DK 3271392T3 DK 16720043 T DK16720043 T DK 16720043T DK 3271392 T3 DK3271392 T3 DK 3271392T3
Authority
DK
Denmark
Prior art keywords
hyperopia
myopia
therapeutic
agents
prophylactic treatment
Prior art date
Application number
DK16720043.5T
Other languages
English (en)
Inventor
Shefali Brinda Jonas
Jost B Jonas
Songhomitra Panda-Jonas
Rahul Arvo Jonas
Original Assignee
Shefali Brinda Jonas
Rahul Arvo Jonas
Jost B Jonas
Panda Jonas Songhomitra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shefali Brinda Jonas, Rahul Arvo Jonas, Jost B Jonas, Panda Jonas Songhomitra filed Critical Shefali Brinda Jonas
Application granted granted Critical
Publication of DK3271392T3 publication Critical patent/DK3271392T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/485Epidermal growth factor [EGF] (urogastrone)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
DK16720043.5T 2015-03-16 2016-03-15 Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia DK3271392T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15000771.4A EP3070101A1 (en) 2015-03-16 2015-03-16 Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia
PCT/EP2016/000460 WO2016146254A1 (en) 2015-03-16 2016-03-15 Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia

Publications (1)

Publication Number Publication Date
DK3271392T3 true DK3271392T3 (da) 2021-08-16

Family

ID=52807497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16720043.5T DK3271392T3 (da) 2015-03-16 2016-03-15 Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia

Country Status (8)

Country Link
US (2) US11008385B2 (da)
EP (2) EP3070101A1 (da)
JP (2) JP7197271B2 (da)
KR (2) KR20170126496A (da)
CN (1) CN107428812A (da)
DK (1) DK3271392T3 (da)
ES (1) ES2883244T3 (da)
WO (1) WO2016146254A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3070101A1 (en) * 2015-03-16 2016-09-21 Universität Heidelberg Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia
EP3532891A4 (en) * 2016-10-25 2020-04-29 Brien Holden Vision Institute Limited DEVICES, SYSTEMS AND / OR METHODS FOR CONTROLLING SHORT-VISION
JP7097845B2 (ja) * 2019-04-23 2022-07-08 ジェネシスヘルスケア株式会社 近視のリスクを判定する方法
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000504206A (ja) * 1995-12-22 2000-04-11 イノジェネティックス・ナムローゼ・フェンノートシャップ 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物
EP1449538A1 (en) 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
ES2639056T3 (es) * 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
KR102272213B1 (ko) * 2014-07-08 2021-07-01 삼성전자주식회사 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도
CA2975362A1 (en) * 2015-02-06 2016-08-11 Navigo Proteins Gmbh Egfr binding proteins comprising ubiquitin muteins
EP3070101A1 (en) * 2015-03-16 2016-09-21 Universität Heidelberg Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia

Also Published As

Publication number Publication date
EP3271392B1 (en) 2021-05-19
JP2018518452A (ja) 2018-07-12
JP2021119187A (ja) 2021-08-12
ES2883244T3 (es) 2021-12-07
WO2016146254A8 (en) 2016-11-24
CN107428812A (zh) 2017-12-01
EP3070101A1 (en) 2016-09-21
US11008385B2 (en) 2021-05-18
US20210340237A1 (en) 2021-11-04
EP3271392A1 (en) 2018-01-24
JP7197271B2 (ja) 2022-12-27
WO2016146254A1 (en) 2016-09-22
KR20210091826A (ko) 2021-07-22
US20190085065A1 (en) 2019-03-21
KR20170126496A (ko) 2017-11-17

Similar Documents

Publication Publication Date Title
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
DK3395353T3 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
HK1219782A1 (zh) 用於預防和/或減慢近視發展的與瞳孔大小無關的鏡片設計和方法
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3139903T3 (da) Vandig oftalmisk opløsning og fremgangsmåde til behandling af tørre øjne-syndrom
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3261642T3 (da) Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3160234T3 (da) Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
DK3271392T3 (da) Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
IL246855A0 (en) Materials for use in the treatment of retinitis
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser